Exnise Nasal Spray 0.05% w/v

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Therapeutic

Prescription Only

SPRAY, SUSPENSION

DOSAGE AND ADMINISTRATION: Prior to administration of the first dose, shake container well and actuate pump 10 times (until a uniform spray is obtained). Each actuation delivers approximately 100 mg of mometasone furoate suspension, containing mometasone furoate monohydrate equivalent to 50 micrograms mometasone furoate. If the spray pump has not been used for 14 days or longer, it should be reprimed with at least 2 actuations, until a uniform spray is observed, before next use. Shake container well before each use. The bottle should be discarded after the labelled number of actuations or within 2 months of first use. Tell your doctor if you accidentally use more than you were told. Cleaning your nasal spray: - It is important to clean your nasal spray regularly, otherwise it may not work properly. - Remove the dust cap and gently pull off the nozzle. - Wash the nozzle and dust cap in warm water and then rinse under a running tap. - Do not try to unblock the nasal applicator by inserting a pin or other sharp object as this will damage the applicator and cause you not to get the right dose of medicine. - Allow the dust cap and nozzle to dry in a warm place. - Push the nozzle back onto the bottle and replace the dust cap. - The spray will need to be primed again with 2 sprays when first used after cleaning. Adults (including geriatric patients) and children 12 years of age and older: The usual recommended dose for prophylaxis and treatment is two sprays (50 micrograms/spray) in each nostril once daily (total dose 200 micrograms). Once symptoms are controlled, dose reduction to one spray in each nostril (total dose 100 micrograms) may be effective for maintenance. If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of four sprays in each nostril once daily (total dose 400 micrograms). Dose reduction is recommended following control of symptoms. Clinically significant onset of action occurs as early as 12 hours after the first dose. Children between the ages of 2 and 11 years: The usual recommended dose is one spray (50micrograms/spray) in each nostril once daily (total dose 100 micrograms). Administration to young children should be aided by an adult. Nasal Polyposis: Adults (including geriatric patients) and adolescents 18 years of age and older: The usual recommended dose for polyposis is two sprays (50 micrograms/spray) in each nostril once daily (total daily dose of 200mcg). If symptoms are inadequately controlled, the dose may be increased to a daily dose of two sprays in each nostril twice daily (total daily dose of 400mcg). Dose reduction is recommended following control of symptoms. Acute rhinosinusitis: The usual recommended dose for acute rhinosinusitis is two sprays (50 micrograms/spray) in each nostril twice daily (total daily dose of 400mcg). If no improvement is seen after 15 days of twice daily administration, alternative therapies should be considered. If symptoms worsen during treatment, the patients should be advised to consult their physician.